Functional synergy between CD40 ligand and HIV-1 Tat contributes to inflammation: Implications in HIV type 1 dementia

Journal of Immunology

Volumn 178, Issue 5, 2007, Pages 3226-3236

  Sui, Ziye ^a   Sniderhan, Lynn F ^a   Schifitto, Giovanni ^a   Phipps, Richard P ^a   Gelbard, Harris A ^a   Dewhurst, Stephen ^a   Maggirwar, Sanjay B ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL CELL; ARTICLE; BLOOD LEVEL; CELL ACTIVATION; CELL SURVIVAL; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEMENTIA; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INFLAMMATION; MACROPHAGE; MALE; MICROGLIA; MONOCYTE; MOUSE; NEUROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

EID: 33847411179     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.5.3226     Document Type: Article

References (65)

1. Kaul, M., and S. A. Lipton. 2006. Mechanisms of neuronal injury and death in HIV-1 associated dementia. Curr. HIV Res. 4: 307-318.
2. Ghafouri, M., S. Amini, K. Khalili, and B. E. Sawaya. 2006. HIV-1 associated dementia: symptoms and causes. Retrovirology 3: 28.
3. Rumbaugh, J. A., and A. Nath. 2006. Developments in HIV neuropathogenesis. Curr. Pharm. Des. 12: 1023-1044.
4. Bruce-Keller, A. J., A. Chauhan, F. O. Dimayuga, J. Gee, J. N. Keller, and A. Nath. 2003. Synaptic transport of human immunodeficiency virus-Tat protein causes neurotoxicity and gliosis in rat brain. J. Neurosci. 23: 8417-8422.
5. Adle-Biassette, H., F. Chretien, L. Wingertsmann, C. Hery, T. Ereau, F. Scaravilli, M. Tardieu, and F. Gray. 1999. Neuronal apoptosis does not correlate with dementia in HIV infection but is related to microglial activation and axonal damage. Neuropathol. Appl. Neurobiol. 25: 123-133.
6. Avison, M. I., A. Nath, R. Greene-Avison, F. A. Schmitt, R. A. Bales, A. Ethisham, R. N. Greenberg, and J. R. Berger. 2004. Inflammatory changes and breakdown of microvascular integrity in early human immunodeficiency virus dementia. J. Neurovirol. 10: 223-232.
7. Gray, F., F. Chretien, A. V. Vallat-Decouvelaere, and F. Scaravilli. 2003. The changing pattern of HIV neuropathology in the HAART era. J Neuropathol. Exp. Neurol. 62: 429-440.
8. Lambotte, O., K. Deiva, and M. Tardieu. 2003. HIV-1 persistence, viral reservoir, and the central nervous system in the HAART era. Brain Pathol. 13: 95-103.
9. Magen, E., D. Elbirt, and Z. Sthoeger. 2005. Cardiovascular disease prevention and treatment in patients with human immunodeficiency virus. Isr. Med. Assoc. J. 7: 252-256.
10. McArthur, J. C., M. P. McDermott, D. McClemon, C. St. Hillaire, K. Conant, K. Marder, G. Schifitto, O. A. Selnes, N. Sacktor, Y. Stem, et al. 2004. Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch. Neurol. 61: 1687-1696.
11. Fischer-Smith, T., and J. Rappaport. 2005. Evolving paradigms in the pathogenesis of HIV-1-associated dementia. Expert Rev. Mol. Med. 7: 1-26.
12. de Gaetano Donati, K., R. Rabagliati, L. Iacoviello, and R. Cauda. 2004. HIV infection, HAART, and endothelial adhesion molecules: current perspectives. Lancet Infect. Dis. 4: 213-222.
13. Janier, M., B. Flageul, L. Drouet, M. L. Scrobohaci, J. M. Villette, A. Palangie, and F. Cottenot. 1988. Cutaneous and plasma values of von Willebrand factor in AIDS: a marker of endothelial stimulation? J. Invest. Dermatol. 90: 703-707.
14. + T-cell counts. Clin. Diagn. Lab. Immunol. 9: 558-561.
15. Wolf, K., D. A. Tsakiris, R. Weber, P. Erb, and M. Battegay. 2002. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J. Infect. Dis. 185: 456-462.
16. Gelbard, H. A., H. S. Nottet, S. Swindells, M. Jett, K. A. Dzenko, P. Genis, R. White, L. Wang, Y. B. Choi, D. Zhang, et al. 1994. Platelet-activating factor: a candidate human immunodeficiency virus type 1-induced neurotoxin. J. Virol. 68: 4628-4635.
17. Aukrust, P., S. Bjornsen, B. Lunden, K. Otterdal, E. C. Ng, W. Ameln, T. Ueland, F. Muller, N. O. Solum, F. Brosstad, and S. S. Froland. 2000. Persistently elevated levels of von Willebrand factor antigen in HIV infection: downregulation during highly active antiretroviral therapy. Thromb. Haemost. 84: 183-187.
18. de Larranaga, G. F., A. R. Bocassi, L. M. Puga, B. S. Alonso, and J. A. Benetucci. 2003. Endothelial markers and HIV infection in the era of highly active antiretroviral treatment. Thromb. Res. 110: 93-98.
19. Khovidhunkit, W., R. A. Memon, J. K. Shigenaga, M. Pang, M. Schambelan, K. Mulligan, K. R. Feingold, and C. Grunfeld. 1999. Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Metabolism 48: 1524-1531.
20. van Kooten, C., and J. Banchereau. 2000. CD40-CD40 ligand. J. Leukocyte Biol. 67: 2-17.
21. Mazzei, G. J., M. D. Edgerton, C. Losberger, S. Lecoanet-Henchoz, P. Graber, A. Durandy, J. F. Gauchat, A. Bernard, B. Allet, and J. Y. Bonnefoy. 1995. Recombinant soluble trimeric CD40 ligand is biologically active. J. Biol. Chem. 270: 7025-7028.
22. Graf, D., S. Muller, U. Korthauer, C. van Kooten, C. Weise, and R. A. Kroczek. 1995. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur. J. Immunol. 25: 1749-1754.
23. Townsend, K. P., D. R. Shytle, Y. Bai, N. San, J. Zeng, M. Freeman, T. Mori, F. Fernandez, D. Morgan, P. Sanberg, and J. Tan. 2004. Lovastatin modulation of microglial activation via suppression of functional CD40 expression. J. Neurosci. Res. 78: 167-176.
24. Hollenbaugh, D., N. Mischel-Petty, C. P. Edwards, J. C. Simon, R. W. Denfeld, P. A. Kiener, and A. Aruffo. 1995. Expression of functional CD40 by vascular endothelial cells. J. Exp. Med. 182: 33-40.
25. Caux, C., N. Burdin, L. Galibert, P. Hermann, N. Renard, C. Servet-Delprat, and J. Banchereau. 1994. Functional CD40 on B lymphocytes and dendritic cells. Res. Immunol. 145: 235-239; discussion 244-239.
26. Abdel-Haq, N., H. N. Hao, and W. D. Lyman. 1999. Cytokine regulation of CD40 expression in fetal human astrocyte cultures. J. Neuroimmunol. 101: 7-14.
27. Kehry, M. R., and B. E. Castle. 1994. Regulation of CD40 ligand expression and use of recombinant CD40 ligand for studying B cell growth and differentiation. Semin. Immunol. 6: 287-294.
28. Ryan, E. P., S. J. Pollock, T. I. Murant, S. H. Bernstein, R. E. Felgar, and R. P. Phipps. 2005. Activated human B lymphocytes express cyclooxygenase-2 and cyclooxygenase inhibitors attenuate antibody production. J. Immunol. 174: 2619-2626.
29. Ray, D. M., F. Akbiyik, S. H. Bernstein, and R. P. Phipps. 2005. CD40 engagement prevents peroxisome proliferator-activated receptor γ agonist-induced apoptosis of B lymphocytes and B lymphoma cells by an NF-κB-dependent mechanism. J. Immunol. 174: 4060-4069.
30. Marder, K., S. M. Albert, M. P. McDermott, J. C. McArthur, G. Schifitto, O. A. Selnes, N. Sacktor, Y. Stern, D. Palumbo, K. Kieburtz, et al. 2003. Interrater reliability of a clinical staging of HIV-associated cognitive impairment. Neurology 60: 1467-1473.
31. Clinical Confirmation of the American Academy of Neurology Algorithm for HIV-1-Associated Cognitive/Motor Disorder. 1996. The Dana consortium on therapy for HIV dementia and related cognitive disorders. Neurology 47: 1247-1253.
32. Akbiyik, F., D. M. Ray, K. F. Gettings, N. Blumberg, C. W. Francis, and R. P. Phipps. 2004. Human bone marrow megakaryocytes and platelets express PPARγ, and PPARγ agonists blunt platelet release of CD40 ligand and thromboxanes. Blood 104: 1361-1368.
33. Sui, Z., S. Fan, L. Sniderhan, E. Reisinger, A. Litzburg, G. Schifitto, H. A. Gelbard, S. Dewhurst, and S. B. Maggirwar. 2006. Inhibition of mixed lineage kinase 3 prevents HIV-1 Tat-mediated neurotoxicity and monocyte activation. J. Immunol. 177: 702-711.
34. Kaufman, J., P. J. Sime, and R. P. Phipps. 2004. Expression of CD154 (CD40 ligand) by human lung fibroblasts: differential regulation by IFN-γ and IL-13, and implications for fibrosis. J. Immunol. 172: 1862-1871.
35. Kovacs, A. D., S. Chakraborty-Sett, S. H. Ramirez, L. F. Sniderhan, A. L. Williamson, and S. B. Maggirwar. 2004. Mechanism of NF-κB inactivation induced by survival signal withdrawal in cerebellar granule neurons. Eur. J. Neurosci. 20: 345-352.
36. Sanchez, J. F., L. F. Sniderhan, A. L. Williamson, S. Fan, S. Chakraborty-Sett, and S. B. Maggirwar. 2003. Glycogen synthase kinase 3β-mediated apoptosis of primary cortical astrocytes involves inhibition of nuclear factor κB signaling. Mol. Cell. Biol. 23: 4649-4662.
37. Ramirez, S. H., S. Fan, C. A. Maguire, S. Perry, K. Hardiek, V. Ramkumar, H. A. Gelbard, S. Dewhurst, and S. B. Maggirwar. 2004. Activation of adenosine A2A receptor protects sympathetic neurons against nerve growth factor withdrawal. J. Neurosci. Res. 77: 258-269.
38. Sun, H. Y., M. J. Chen, C. C. Hung, M. Y. Chen, S. M. Hsieh, W. H. Sheng, C. T. Fang, S. Y. Chang, and S. C. Chang. 2004. Clinical presentations and virologic characteristics of primary human immunodeficiency virus type-1 infection in a university hospital in Taiwan. J. Microbiol. Immunol. Infect. 37: 271-275.
39. Holme, P. A., F. Muller, N. O. Solum, F. Brosstad, S. S. Froland, and P. Aukrust. 1998. Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection. FASEB J. 12: 79-89.
40. Andre, P., L. Nannizzi-Alaimo, S. K. Prasad, and D. R. Phillips. 2002. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 106: 896-899.
41. Pu, H., J. Tian, G. Flora, Y. W. Lee, A. Nath, B. Hennig, and M. Toborek. 2003. HIV-1 Tat protein upregulates inflammatory mediators and induces monocyte invasion into the brain. Mol. Cell. Neurosci. 24: 224-237.
42. + peripheral blood-derived monocytes in HIV dementia: perivascular accumulation and reservoir of HIV infection. J. Neurovirol. 7: 528-541.
43. Lafrenie, R. M., L. M. Wahl, J. S. Epstein, K. M. Yamada, and S. Dhawan. 1997. Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression. J. Immunol. 159: 4077-4083.
44. Brake, D. A., C. Debouck, and G. Biesecker. 1990. Identification of an Arg-Gly-Asp (RGD) cell adhesion site in human immunodeficiency virus type 1 transactivation protein, tat. J. Cell Biol. 111: 1275-1281.
45. Thomas, D. M., D. M. Francescutti-Verbeem, and D. M. Kuhn. 2006. Gene expression profile of activated microglia under conditions associated with dopamine neuronal damage. FASEB J. 20: 515-517.
46. Lee, C., B. Tomkowicz, B. D. Freedman, and R. G. Collman. 2005. HIV-1 gp120-induced TNF-α production by primary human macrophages is mediated by phosphatidylinositol-3 (PI-3) kinase and mitogen-activated protein (MAP) kinase pathways. J. Leukocyte Biol. 78: 1016-1023.
47. Contreras, X., Y. Bennasser, N. Chazal, and E. Bahraoui. 2003. HIV-1 Tat induces TNF-α production by human monocytes: involvement of calcium and PKC pathways. J. Soc. Biol. 197: 267-275.
48. Lappas, M., K. Yee, M. Permezel, and G. E. Rice. 2005. Sulfasalazine and BAY 11-7082 interfere with the nuclear factor-κB and IκB kinase pathway to regulate the release of proinflammatory cytokines from human adipose tissue and skeletal muscle in vitro. Endocrinology 146: 1491-1497.
49. Tone, M., Y. Tone, J. M. Babik, C. Y. Lin, and H. Waldmann. 2002. The role of Sp1 and NF-κB in regulating CD40 gene expression. J. Biol. Chem. 277: 8890-8897.
50. Ramirez, S. H., J. F. Sanchez, C. A. Dimitri, H. A. Gelbard, S. Dewhurst, and S. B. Maggirwar. 2001. Neurotrophins prevent HIV Tat-induced neuronal apoptosis via a nuclear factor-κB (NF-κB)-dependent mechanism. J. Neurochem. 78: 874-889.
51. Wachtman, L. M., P. M. Tarwater, S. E. Queen, R. J. Adams, and J. L. Mankowski. 2006. Platelet decline: an early predictive hematologic marker of simian immunodeficiency virus central nervous system disease. J. Neurovirol. 12: 25-33.
52. Tsakiris, D. A., M. Tschopl, F. Wolf, K. H. Labs, K. A. Jager, and G. A. Marbet. 2000. Platelets and cytokines in concert with endothelial activation in patients with peripheral arterial occlusive disease. Blood Coagul. Fibrinolysis 11: 165-173.
53. Heeschen, C., S. Dimmeler, C. W. Hamm, M. J. van den Brand, E. Boersma, A. M. Zeiher, and M. L. Simoons. 2003. Soluble CD40 ligand in acute coronary syndromes. N. Engl. J. Med 348: 1104-1111.
54. Devaraj, S., N. Glaser, S. Griffen, J. Wang-Polagruto, E. Miguelino, and I. Jialal. 2006. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 55: 774-779.
55. D'Aversa, T. G., E. A. Eugenin, and J. W. Berman. 2005. NeuroAIDS: contributions of the human immunodeficiency virus-1 proteins Tat and gp120 as well as CD40 to microglial activation. J. Neurosci. Res. 81: 436-446.
56. Mayne, M., C. P. Holden, A. Nath, and J. D. Geiger. 2000. Release of calcium from inositol 1,4,5-trisphosphate receptor-regulated stores by HIV-1 Tat regulates TNF-α production in human macrophages. J. Immunol. 164: 6538-6542.
57. Contreras, X., Y. Bennasser, N. Chazal, M. Moreau, C. Leclerc, J. Tkaczuk, and E. Bahraoui. 2005. Human immunodeficiency virus type 1 Tat protein induces an intracellular calcium increase in human monocytes that requires DHP receptors: involvement in TNF-α production. Virology 332: 316-328.
58. Albini, A., S. Ferrini, R. Benelli, S. Sforzini, D. Giunciuglio, M. G. Aluigi, A. E. Proudfoot, S. Alouani, T. N. Wells, G. Mariani, et al. 1998. HIV-1 Tat protein mimicry of chemokines. Proc. Natl. Acad. Sci. USA 95: 13153-13158.
59. Ponomarev, E. D., L. P. Shriver, and B. N. Dittel. 2006. CD40 expression by microglial cells is required for their completion of a two-step activation process during central nervous system autoimmune inflammation. J. Immunol. 176: 1402-1410.
60. Matzen, K., A. E. Dirkx, M. G. oude Egbrink, C. Speth, M. Gotte, G. Ascherl, T. Grimm, A. W. Griffioen, and M. Sturzt. 2004. HIV-1 Tat increases the adhesion of monocytes and T-cells to the endothelium in vitro and in vivo: implications for AIDS-associated vasculopathy. Virus Res. 104: 145-155.
61. Fotheringham, J., M. Mayne, C. Holden, A. Nath, and J. D. Geiger. 2004. Adenosine receptors control HIV-1 Tat-induced inflammatory responses through protein phosphatase. Virology 327: 186-195.
62. Westendorp, M. O., R. Frank, C. Ochsenbauer, K. Stricker, J. Dhein, H. Walczak, K. M. Debatin, and P. H. Krammer. 1995. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 375: 497-500.
63. Nath, A., N. J. Haughey, M. Jones, C. Anderson, J. E. Bell, and J. D. Geiger. 2000. Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. Ann. Neurol. 47: 186-194.
64. Perry, S. W., J. A. Hamilton, L. W. Tjoelker, G. Dbaibo, K. A. Dzenko, L. G. Epstein, Y. Hannun, J. S. Whittaker, S. Dewhurst, and H. A. Gelbard. 1998. Platelet-activating factor receptor activation: an initiator step in HIV-1 neuropathogenesis. J. Biol. Chem. 273: 17660-17664.
65. Vishnevetsky, D., V. A. Kiyanista, and P. J. Gandhi. 2004. CD40 ligand: a novel target in the fight against cardiovascular disease. Ann. Pharmacother. 38: 1500-1508.